157 related articles for article (PubMed ID: 32385029)
1. [Significance of Dynamic Risk Assessment in the Follow-up of Non-distant Metastatic Differentiated Thyroid Cancer Patients with Intermediate and High Risk].
Liu JR; Liu YQ; Li H; Liang J; Lin YS
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2020 Apr; 42(2):222-227. PubMed ID: 32385029
[No Abstract] [Full Text] [Related]
2. Serum thyrotropin level of 30 μIU/mL is inadequate for preablative thyroglobulin to serve as a prognostic marker for differentiated thyroid cancer.
Zhao T; Liang J; Guo Z; Li J; Lin Y
Endocrine; 2016 Jul; 53(1):166-73. PubMed ID: 26782372
[TBL] [Abstract][Full Text] [Related]
3. In Patients With Low- to Intermediate-Risk Thyroid Cancer, a Preablative Thyrotropin Level of 30 μIU/mL Is Not Adequate to Achieve Better Response to 131I Therapy.
Zhao T; Liang J; Guo Z; Li T; Lin Y
Clin Nucl Med; 2016 Jun; 41(6):454-8. PubMed ID: 26914559
[TBL] [Abstract][Full Text] [Related]
4. UNFAVORABLE RESPONSES TO RADIOIODINE THERAPY IN N1B PAPILLARY THYROID CANCER: A PROPENSITY SCORE MATCHING STUDY.
Liu YQ; Li H; Liu JR; Lin YS
Endocr Pract; 2019 Dec; 25(12):1286-1294. PubMed ID: 31412228
[No Abstract] [Full Text] [Related]
5. Is TSH suppression still necessary in intermediate- and high-risk papillary thyroid cancer patients with pre-ablation stimulated thyroglobulin <1 ng/mL before the first disease assessment?
Tian T; Huang R; Liu B
Endocrine; 2019 Jul; 65(1):149-154. PubMed ID: 30924085
[TBL] [Abstract][Full Text] [Related]
6. Delayed initial radioiodine therapy related to incomplete response in low- to intermediate-risk differentiated thyroid cancer.
Li H; Zhang YQ; Wang C; Zhang X; Li X; Lin YS
Clin Endocrinol (Oxf); 2018 Apr; 88(4):601-606. PubMed ID: 29338092
[TBL] [Abstract][Full Text] [Related]
7. Thyroglobulin levels measured at the time of remnant ablation to predict response to treatment in differentiated thyroid cancer after thyroid hormone withdrawal or recombinant human TSH.
Pitoia F; Abelleira E; Cross G
Endocrine; 2017 Jan; 55(1):200-208. PubMed ID: 27655291
[TBL] [Abstract][Full Text] [Related]
8. A Follow-Up Strategy for Patients with an Excellent Response to Initial Therapy for Differentiated Thyroid Carcinoma: Less Is Better.
Jeon MJ; Kim M; Park S; Oh HS; Kim TY; Kim WB; Shong YK; Kim WG
Thyroid; 2018 Feb; 28(2):187-192. PubMed ID: 29179642
[TBL] [Abstract][Full Text] [Related]
9. Delayed Initial Radioiodine Adjuvant Therapy Does Affect Biochemical Response in Intermediate- to High-Risk Differentiated Thyroid Cancer.
Yu F; Li X; Ji Y; Tan J; Zhang G; Wang P; He Y; Wang R
Front Endocrinol (Lausanne); 2021; 12():743310. PubMed ID: 34858329
[TBL] [Abstract][Full Text] [Related]
10. IS IT WORTH SUPPRESSING TSH IN LOW- AND INTERMEDIATE-RISK PAPILLARY THYROID CANCER PATIENTS BEFORE THE FIRST DISEASE ASSESSMENT?
Lamartina L; Montesano T; Falcone R; Biffoni M; Grani G; Maranghi M; Ciotti L; Giacomelli L; Ramundo V; Lomonaco C; Di Gioia CR; Piernatale L; Ronga G; Durante C
Endocr Pract; 2019 Feb; 25(2):165-169. PubMed ID: 30383494
[TBL] [Abstract][Full Text] [Related]
11. Individualized Follow-Up Strategy for Patients with an Indeterminate Response to Initial Therapy for Papillary Thyroid Carcinoma.
Oh HS; Ahn JH; Song E; Han JM; Kim WG; Kim TY; Kim WB; Shong YK; Jeon MJ
Thyroid; 2019 Feb; 29(2):209-215. PubMed ID: 30384812
[TBL] [Abstract][Full Text] [Related]
12. Dynamic Risk Estimates of Outcome in Chinese Patients with Well-Differentiated Thyroid Cancer After Total Thyroidectomy and Radioactive Iodine Remnant Ablation.
Shen FC; Hsieh CJ; Huang IC; Chang YH; Wang PW
Thyroid; 2017 Apr; 27(4):531-536. PubMed ID: 28007013
[TBL] [Abstract][Full Text] [Related]
13. Disease Progression in Papillary Thyroid Cancer with Biochemical Incomplete Response to Initial Therapy.
Zern NK; Clifton-Bligh R; Gill AJ; Aniss A; Sidhu S; Delbridge L; Learoyd D; Robinson B; Sywak M
Ann Surg Oncol; 2017 Sep; 24(9):2611-2616. PubMed ID: 28585075
[TBL] [Abstract][Full Text] [Related]
14. Management of thyroid cancer: United Kingdom National Multidisciplinary Guidelines.
Mitchell AL; Gandhi A; Scott-Coombes D; Perros P
J Laryngol Otol; 2016 May; 130(S2):S150-S160. PubMed ID: 27841128
[TBL] [Abstract][Full Text] [Related]
15. Impact factors of benefiting from initial 131 I ablation in patients with intermediate-risk differentiated thyroid carcinoma: a study based on a re-evaluation of therapeutic response.
Ren L; Hu Y; Hu Y; Xiao D; Sun J; Zhu B; Zhang C
Nucl Med Commun; 2024 Mar; 45(3):188-195. PubMed ID: 38165164
[TBL] [Abstract][Full Text] [Related]
16. Ongoing risk stratification for differentiated thyroid cancer (DTC) - stimulated serum thyroglobulin (Tg) before radioiodine (RAI) ablation, the most potent risk factor of cancer recurrence in M0 patients.
Krajewska J; Jarząb M; Czarniecka A; Roskosz J; Kukulska A; Handkiewicz-Junak D; Puch Z; Wygoda Z; Paliczka-Cieślik E; Kropińska A; Gubała E; Jurecka-Lubieniecka B; Jarząb B
Endokrynol Pol; 2016; 67(1):2-11. PubMed ID: 26884109
[TBL] [Abstract][Full Text] [Related]
17. Monitoring differentiated thyroid cancer patients with negative serum thyroglobulin. Diagnostic implication of TSH-stimulated antithyroglobulin antibody.
Nam HY; Paeng JC; Chung JK; Kang KW; Cheon GJ; Kim Y; Park DJ; Park YJ; Min HS; Lee DS
Nuklearmedizin; 2014; 53(2):32-8. PubMed ID: 24276613
[TBL] [Abstract][Full Text] [Related]
18. Non-suppressed thyrotropin and elevated thyroglobulin are independent predictors of recurrence in differentiated thyroid carcinoma.
Böhm J; Kosma VM; Eskelinen M; Hollmen S; Niskanen M; Tulla H; Alhava E; Niskanen L
Eur J Endocrinol; 1999 Nov; 141(5):460-7. PubMed ID: 10576761
[TBL] [Abstract][Full Text] [Related]
19. Dynamic prediction of the risk of recurrence in patients over 60 years of age with differentiated thyroid carcinoma.
Morosán YJ; Parisi C; Urrutia MA; Rosmarin M; Schnitman M; Serrano L; Luciani W; Faingold C; Pitoia F; Brenta G
Arch Endocrinol Metab; 2016 Aug; 60(4):348-54. PubMed ID: 26910621
[TBL] [Abstract][Full Text] [Related]
20. Is diagnostic iodine-131 scanning with recombinant human TSH useful in the follow-up of differentiated thyroid cancer after thyroid ablation?
Mazzaferri EL; Kloos RT
J Clin Endocrinol Metab; 2002 Apr; 87(4):1490-8. PubMed ID: 11932270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
